Incyte Corp. (INCY) said Thursday that the U.S. Food and Drug Administration has accepted for Priority Review its supplemental New Drug Application or sNDA for ruxolitinib, or Jakafi, for the treatment of patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
from RTT - Biotech https://ift.tt/2D7YEiK
via IFTTT
No comments:
Post a Comment